Protek Pharmaceuticals Private Limited
About Protek Pharmaceuticals Private Limited
Data last updated:
Protek Pharmaceuticals Private Limited is a private limited company based in Patna, Bihar, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 13 February 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Patna, under CIN U85191BR2012PTC018166. Its GSTIN is 10AAGCP4473M1ZA (Bihar).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1.2 Lakh. It is led by directors Mukesh Kumar Singh and Sangita Kumari.
Its last annual general meeting (AGM) was held on 28 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Geeta Niwas Ashok Nagar Road No – 11 Kankarbagh, Patna, Bihar, India – 800020.
As per the financials filed for FY 2023, the company reported a revenue of ₹6.88 Lakh, a growth of 16% compared to the previous year. For the same year it recorded a net loss of ₹1.72 Lakh (net margin -24.9%) and EBITDA of -₹1.71 Lakh (EBITDA margin -24.9%). Revenue has declined at a compounded annual rate (CAGR) of 13% over three years and 14% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Protek Pharmaceuticals Private Limited's registered office is in Patna, Bihar. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressGeeta Niwas Ashok Nagar Road No – 11 Kankarbagh, Patna, Bihar, India – 800020
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Protek Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Protek Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Protek Pharmaceuticals Private Limited, buy the company report.
Financials of Protek Pharmaceuticals Private Limited
FY 2023 filings availableProtek Pharmaceuticals Private Limited reported revenue of ₹6.88 Lakh (up 16% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue rose 16% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 14%. EBITDA fell 54% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹1.71 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.72 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -24.9% | ||||
| Net Profit Margin | -24.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Protek Pharmaceuticals Private Limited, buy the company report.
Board of directors of Protek Pharmaceuticals Private Limited
Protek Pharmaceuticals has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mukesh Kumar Singh | Director | 21 Aug 2017 | 9 Years 2 Months | Current |
| Sangita Kumari | Director | 13 Feb 2012 | 14 Years 8 Months | Current |
Peer comparison
Protek Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Admit Pharmaceuticals Private Limited | ₹6.97 Lakh (FY 2024) | -14.0% | Ahmedabad, Gujarat, India | |||
| Eravic Pharmaceuticals Private Limited | ₹6.91 Lakh (FY 2021) | 111.0% | Lucknow, Uttar Pradesh, India | |||
| Asdr India Pharmaceuticals Private Limited | ₹6.9 Lakh (FY 2019) | -42.0% | Dehradun, Uttarakhand, India | |||
| Protek Pharmaceuticals Private Limitedthis company | ₹6.88 Lakh (FY 2023) | -₹1.72 Lakh | -24.9% | 16.0% | Patna, Bihar, India | |
| Martin and Harris Pharmaceuticals Private Limited | ₹6.87 Lakh (FY 2022) | 15.0% | Mohali, Punjab, India |
To see the full peer comparison of Protek Pharmaceuticals Private Limited, buy the company report.
Auditor
Protek Pharmaceuticals Private Limited is audited by VIMAL SHARUGHAN & CO. for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VIMAL SHARUGHAN & CO. | FY 2017 | 010329C |
Shareholding
The shareholding of Protek Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Protek Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Protek Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Protek Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Protek Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAGCP4473M1ZA | Bihar | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Protek Pharmaceuticals Private Limited, buy the company report.
Recent activity
Protek Pharmaceuticals Private Limited has 4 board changes on record since 2012: 2 appointments and 2 cessations. The latest: Mukesh Kumar Singh was appointed as Director on 21 Aug 2017.
Frequently asked questions
Protek Pharmaceuticals is an active private limited company based in Patna, Bihar, India. The company works in wholesale, within the trading industry. It was incorporated on 13 February 2012 (14+ years old) and is registered under CIN U85191BR2012PTC018166.
Protek Pharmaceuticals has 2 current directors:
- Mukesh Kumar Singh - Director
- Sangita Kumari - Director
The latest financial statements of Protek Pharmaceuticals on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 28 September 2023. Year-wise statements from 2015 are in the company report.
The GSTIN of Protek Pharmaceuticals is 10AAGCP4473M1ZA, registered in Bihar.
The CIN (Corporate Identification Number) of Protek Pharmaceuticals is U85191BR2012PTC018166. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Protek Pharmaceuticals was incorporated on 13 February 2012, making it 14+ years old. It is registered with the Registrar of Companies, Patna.
The peers of Protek Pharmaceuticals by revenue are Admit Pharmaceuticals Private Limited, Eravic Pharmaceuticals Private Limited, Asdr India Pharmaceuticals Private Limited, Martin and Harris Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Mukesh Kumar Singh was appointed as Director on 21 Aug 2017. Kundan Kumar ceased to be Director on 12 Aug 2017. Mukesh Kumar Singh ceased to be Director on 12 Aug 2017. Protek Pharmaceuticals has 4 board changes on record in total.
The registered office of Protek Pharmaceuticals is at Geeta Niwas Ashok Nagar Road No – 11 Kankarbagh, Patna, Bihar, India – 800020.
Protek Pharmaceuticals operates in the trading industry, in the wholesale segment.
The compliance status of Protek Pharmaceuticals is compliant as of 21 July 2026. The company is actively filing with the Registrar of Companies.